Safety of reducing antibiotic use in children with febrile neutropenia: A systematic review

References

• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–1924. doi:10.1002/cncr.20983.
   PubMed Web of Science ®Google Scholar
• Vedi A, Cohn R. Oral versus intravenous antibiotics in treatment of paediatric febrile neutropenia. J Paediatr Child Health. 2013;49(3):170–178. doi:10.1111/j.1440-1754.2011.02201.x.
   PubMed Web of Science ®Google Scholar
• Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer. 2012;59(3):423–430. doi:10.1002/pbc.24076.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. JCO. 2017;35(18):2082–2094. doi:10.1200/JCO.2016.71.7017.
   PubMed Web of Science ®Google Scholar
• Kebudi R, Kizilocak H. Febrile neutropenia in children with cancer: approach to diagnosis and treatment. Curr Pediatr Rev. 2018;14(3):204–209. doi:10.2174/1573396314666180508121625.
   PubMed Web of Science ®Google Scholar
• Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86(1):126–134. doi:10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol. 2002;39(2):77–85. doi:10.1002/mpo.10073.
   PubMedGoogle Scholar
• Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J. 2003;22(12):1138–1142.
   PubMed Web of Science ®Google Scholar
• Gil-Veloz M, Pacheco-Rosas D, Solórzano-Santos F, Villasís-Keever M, Betanzos-Cabrera Y, Miranda-Novales G. Early discharge of pediatric patients with cancer, fever, and neutropenia with low-risk of systemic infection. Bol Med Hosp Infant Mex. 2018;75(6):352–357.
   PubMed Web of Science ®Google Scholar
• Freifeld A, Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J. 1997;16(1):140–146.
   PubMed Web of Science ®Google Scholar
• Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol. 2009;31(9):635–641. doi:10.1097/MPH.0b013e3181acd8cd.
   PubMed Web of Science ®Google Scholar
• Teuffel O, Amir E, Alibhai SM, Beyene J, Sung L. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics. 2011;127(2):e279–e286. doi:10.1542/peds.2010-0734.
   PubMed Web of Science ®Google Scholar
• Manji A, Beyene J, Dupuis LL, Phillips R, Lehrnbecher T, Sung L. Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children - A systematic review of prospective trials. Support Care Cancer. 2012;20(6):1135–1145. doi:10.1007/s00520-012-1425-8.
   PubMed Web of Science ®Google Scholar
• Maxwell RR, Egan-Sherry D, Gill JB, Roth ME. Management of chemotherapy-induced febrile neutropenia in pediatric oncology patients: a North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. Pediatr Blood Cancer. 2017;64(12):e26700. doi:10.1002/pbc.26700.
   Web of Science ®Google Scholar
• Lehrnbecher T, Phillips R, Alexander S, International Pediatric Fever and Neutropenia Guideline Panel, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427–4438. doi:10.1200/JCO.2012.42.7161.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, PRISMA-P Group, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi:10.1136/bmj.g7647.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Infectious Diseases Society of America, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–e93. doi:10.1093/cid/cir073.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Savović J, Page M. J, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019). Cochrane, 2019. Available from https://www.training.cochrane.org/handbook.
   Google Scholar
• Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019). Cochrane, 2019. Available from https://www.training.cochrane.org/handbook.
   Google Scholar
• Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34(2):87–91. doi:10.1002/(SICI)1096-911X(200002)34:2<87::AID-MPO2>3.0.CO;2-F.
   PubMedGoogle Scholar
• Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer. 2000;88(12):2848–2852. doi:10.1002/1097-0142(20000615)88:12<2848::AID-CNCR27>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis. 2001;32(1):36–43. doi:10.1086/317552.
   PubMed Web of Science ®Google Scholar
• Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97(7):1775–1780. doi:10.1002/cncr.11251.
   PubMed Web of Science ®Google Scholar
• Cagol AR, Castro Junior CG, Martins MC, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J). 2009;85(6):531–535. doi:10.2223/JPED.1956.
   PubMed Web of Science ®Google Scholar
• Avilés-Robles MJ, Reyes-López A, Otero-Mendoza FJ, et al. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: a noninferiority multicenter randomized clinical trial. Pediatr Blood Cancer. 2020;67(6):e28251.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Villarroel M, Avendaño LF, Cofré J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis. 1997;25(1):92–97. doi:10.1086/514500.
   PubMed Web of Science ®Google Scholar
• Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol/Oncol. 2000;22(5):405–411.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Acuna M, et al. Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect. 2017;23(3):173–178.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. JCO. 2001;19(14):3415–3421. doi:10.1200/JCO.2001.19.14.3415.
   PubMed Web of Science ®Google Scholar
• Robinson PD, Lehrnbecher T, Phillips R, Dupuis LL, Sung L. Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials. JCO. 2016;34(17):2054–2060. doi:10.1200/JCO.2015.65.8591.
   PubMed Web of Science ®Google Scholar
• Morgan JE, Cleminson J, Atkin K, Stewart LA, Phillips RS. Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer. 2016;24(6):2651–2660. doi:10.1007/s00520-016-3074-9.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, ESMO Guidelines Committee, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118. doi:10.1093/annonc/mdw325.
   PubMed Web of Science ®Google Scholar
• Cometta A, Kern WV, De Bock R, International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382–389. doi:10.1086/376637.
   PubMed Web of Science ®Google Scholar
• Simon A, Groger N, Wilkesmann A, et al. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents. 2006;28(5):417–422. doi:10.1016/j.ijantimicag.2006.08.007.
   PubMed Web of Science ®Google Scholar
• Reinecke J, Lowas S, Snowden J, Neemann K. Blood stream infections and antibiotic utilization in pediatric leukemia patients with febrile neutropenia. J Pediatr Hematol Oncol. 2019;41(4):251–255. doi:10.1097/MPH.0000000000001279.
   PubMed Web of Science ®Google Scholar
• Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One. 2012;7(5):e38300. doi:10.1371/journal.pone.0038300.
   PubMed Web of Science ®Google Scholar
• Phillips RS, Sung L, Ammann RA, PICNICC Collaboration, et al. Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Br J Cancer. 2016;114(6):623–630. doi:10.1038/bjc.2016.28.
   PubMed Web of Science ®Google Scholar
• Phillips B, Morgan JE, Haeusler GM, Riley RD, PICNICC Collaborative. Individual participant data validation of the PICNICC prediction model for febrile neutropenia. Arch Dis Child. 2020;105(5):439–445. doi:10.1136/archdischild-2019-317308.
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Klassen TP, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol. 2000;53(9):964–972. doi:10.1016/S0895-4356(00)00188-8.
   PubMed Web of Science ®Google Scholar